JHS Svendgaard Laboratories Limited
National Stock Exchange of IndiaTotal Valuation
JHS Svendgaard Laboratories Limited carries a market capitalization of 670.40M, placing it among publicly traded companies globally. Its enterprise value stands at 531.95M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 670.40M |
| Enterprise Value | 531.95M |
Share Statistics
JHS Svendgaard Laboratories Limited currently has 87.41M shares outstanding.
| Shares Outstanding | 87.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.58, and the price-to-book ratio stands at 0.67.
| PE Ratio | N/A |
| PS Ratio | 0.58 |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.34 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 0.52 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 73.80 |
Financial Position
JHS Svendgaard Laboratories Limited maintains a current ratio of 1.95, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.50, indicating elevated leverage, while an interest coverage ratio of -5.68 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.95 |
| Quick Ratio | 0.63 |
| Debt / Equity | 8.50 |
| Debt / EBITDA | -3.04 |
| Interest Coverage | -5.68 |
Financial Efficiency
| Return on Equity (ROE) | -2.80 |
| Return on Assets (ROA) | -0.92 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.82 |
Taxes
| Income Tax | -3.68M |
| Effective Tax Rate | N/A |
Stock Price Statistics
JHS Svendgaard Laboratories Limited's stock has declined approximately -40.54264% over the past 52 weeks. The 50-day moving average sits at 8.43, while the 200-day moving average is 9.81.
| Beta (5Y) | N/A |
| 52-Week Price Change | -40.54264% |
| 50-Day Moving Average | 8.43 |
| 200-Day Moving Average | 9.81 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, JHS Svendgaard Laboratories Limited generated 1.02B in revenue and converted that into -19.22M in net income, yielding earnings per share of -0.21. EBITDA reached -48.80M, while operating income came in at -48.80M.
| Revenue | 1.02B |
| Gross Profit | 364.65M |
| Operating Income | -48.80M |
| Pretax Income | -22.90M |
| Net Income | -19.22M |
| EBITDA | -48.80M |
| EBIT | -48.80M |
| Earnings Per Share (EPS) | -0.21 |
Balance Sheet
JHS Svendgaard Laboratories Limited holds 205.09M in cash and equivalents against 148.51M in total debt, resulting in a net debt position of 110.58M. Total book value stands at 874.06M, with working capital of 308.17M providing operational flexibility.
| Cash & Cash Equivalents | 205.09M |
| Total Debt | 148.51M |
| Net Debt | 110.58M |
| Equity (Book Value) | 874.06M |
| Book Value Per Share | 9.73 |
| Working Capital | 308.17M |
Margins
JHS Svendgaard Laboratories Limited operates with a gross margin of 35.86, reflecting its pricing power and cost economics. The operating margin of -4.80 and net profit margin of -1.89 provide insight into operational efficiency.
| Gross Margin | 35.86 |
| Operating Margin | -4.80 |
| Pretax Margin | -2.25 |
| Profit Margin | -1.89 |
| EBITDA Margin | -4.80 |
Scores
JHS Svendgaard Laboratories Limited posts an Altman Z-Score of 1.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.45 |